Evidence map›Paper›PMID 35901349›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Treatment Delay during Radiotherapy of Cancer Patients due to COVID-19 Pandemic.

Swarupa Mitra, David K Simson, Himanshi Khurana, Sarthak Tandon, Parveen Ahlawat, Nitin Bansal, Soumitra Barik, Jaskaran Singh Sethi, Kundan Singh Chufal, Munish Gairola

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Swarupa MitraDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
David K SimsonDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.ORCID 0000-0001-8270-8042
Himanshi KhuranaDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Sarthak TandonDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Parveen AhlawatDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Nitin BansalDepartment of Infectious Diseases, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Soumitra BarikDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Jaskaran Singh SethiDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Kundan Singh ChufalDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Munish GairolaDepartment of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo analyze the impact of treatment delay caused by COVID-19 infection on patients scheduled for radiotherapy treatment. METHODS AND MATERIALS: In this descriptive study, we analyzed all patients who were COVID-19 positive during the scheduled radiotherapy course, those who had an infection while on neoadjuvant treatment period, or during surgery before the start of radiation. The study period was from June 2020 to May 2021. A treatment delay was defined as a delay in starting the radiation treatment, a gap during their scheduled radiation treatment, or treatment discontinuation. All patients who had a treatment delay were followed-up till November 2021.

resultsThe median follow-up time of the study was 13 months. Ninety-four patients were selected for the study who met the inclusion criteria. Seventy-seven patients had a mild COVID-19 infection, while 17 had a moderate to severe illness. Of the entire cohort, 83 patients had a treatment delay. The median treatment delay (MTD) in days was 18 (6 to 47). Amongst those who had a treatment delay, 66 patients were treated with curative intent, of which 51 patients are on follow-up - 34 patients are disease-free (MTD - 18.5, 10 to 43), seven had either a residual disease or locoregional recurrence (MTD - 22, 10 to 32), seven had distant metastasis (MTD - 18, 15 to 47), and three patients died (MTD - 20, 8 to 27). Of three patients who died, only one died of COVID-19-related causes.

conclusionsEven though the mortality due to COVID-19 infection among those who underwent radiotherapy was low, a treatment delay might have caused adverse treatment outcomes. Longer follow-up of these patients is required to further establish this. It will remain debatable whether it was worth delaying radiotherapy for mild to moderate COVID-19 infection for a significant time to cause a potential cancer treatment failure.

Indexed as

COVID-19HumansNeoadjuvant TherapyNeoplasm Recurrence, LocalPandemicsTime-to-Treatmentcancer patientsCOVID 19Pandemicradiotherapytreatment delay

Identifiers

PMID35901349
PMCPMC9727328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.